January 1, 1978Clinical and Experimental Hypertension

Influence of Angiotensin Antagonists on Renal Vascular Resistance and Prostaglandin E Release

View Full Paper

Ask AI

Bookmark

Population

Pentobarbital anesthetized dogs

Comparison

Intraarterial infusion of angiotensin… vs Baseline and comparison between the two agents

Design

Preclinical

Authors

SSShouma SugawaraUniversity of Minnesota BZBen G. ZimmermanOregon Health & Science University

Discussion

Member takes

Implication

Saralasin's renal vasodilator action in canine occlusion does not support clinical use; leaves open translation of angiotensin antagonism to human renal protection.

Structured PICO

Population

Pentobarbital anesthetized dogs

Intervention

Intraarterial infusion of angiotensin antagonists 1-Sar-8-Ala-angiotensin II (saralasin) (20 and 50-60 ng/ml) or 1-Sar-Ileu-angiotensin II (1-S-8-I A) (10 and 20 ng/ml) before and during partial occlusion of the renal artery (RAO)

Comparator

Baseline (before RAO) and comparison between the two agents

Outcome

Renal vascular resistance (RVR) and prostaglandin E (PGE) releasesurrogate

In a canine model, saralasin exerts a renal vasodilator action during renal artery occlusion via angiotensin antagonism, independent of prostaglandin E release.

Cite This Study

Sugawara et al. (1978) studied this question.

synapsesocial.com/papers/6a6f55412163a0a01bc3a52d https://doi.org/10.3109/10641967809068592

View Full Paper

Ask AI

Bookmark

Implication

Saralasin's renal vasodilator action in canine occlusion does not support clinical use; leaves open translation of angiotensin antagonism to human renal protection.

Influence of Angiotensin Antagonists on Renal Vascular Resistance and Prostaglandin E Release

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Influence of Angiotensin Antagonists on Renal Vascular Resistance and Prostaglandin E Release

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider